Moderna, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Moderna, Inc. (MRNA) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$70.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$16.00M, a 108.16% decline year-over-year.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$54.00M.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$237.00M.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$66.00M, a 144.00% decline year-over-year.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$153.00M.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$145.00M.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.80B, a 179.81% decline from fiscal 2022.
- Moderna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.26B, a 361.76% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$70.00M 10-Q · filed 2026-07-31 | -$307.00M derived: sum of 3 quarters · filed 2026-07-31 | -$373.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$54.00M 10-Q · filed 2026-05-01 | -$291.00M derived: sum of 2 quarters · filed 2026-05-01 | -$357.00M derived: sum of 3 quarters · filed 2026-05-01 | -$161.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$237.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$303.00M derived: sum of 2 quarters · filed 2026-02-20 | -$107.00M derived: sum of 3 quarters · filed 2026-07-31 | -$153.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | -$66.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $130.00M derived: sum of 2 quarters · filed 2026-07-31 | $84.00M 10-Q · filed 2025-11-06 | -$208.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $196.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $150.00M 10-Q · filed 2026-07-31 | -$142.00M derived: sum of 3 quarters · filed 2026-07-31 | $8.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$46.00M 10-Q · filed 2026-05-01 | -$338.00M derived: sum of 2 quarters · filed 2026-05-01 | -$188.00M derived: sum of 3 quarters · filed 2026-05-01 | -$188.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$292.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$142.00M derived: sum of 2 quarters · filed 2026-02-20 | -$142.00M derived: sum of 3 quarters · filed 2026-02-20 | -$145.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $150.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $150.00M derived: sum of 2 quarters · filed 2025-11-06 | $147.00M 10-Q · filed 2025-11-06 | -$883.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$3.00M 10-Q · filed 2025-08-01 | -$1.03B derived: sum of 3 quarters · filed 2026-02-20 | -$1.95B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$3.00M 10-Q · filed 2025-05-01 | -$1.03B derived: sum of 2 quarters · filed 2026-02-20 | -$1.95B derived: sum of 3 quarters · filed 2026-02-20 | -$2.02B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$1.03B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.94B derived: sum of 2 quarters · filed 2026-02-20 | -$2.01B derived: sum of 3 quarters · filed 2026-02-20 | -$1.80B 10-K · filed 2026-02-20 | -$974.00M 10-K · filed 2024-02-23 | |||
| 2023-09-30 | -$914.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$984.00M derived: sum of 2 quarters · filed 2024-11-07 | -$772.00M 10-Q · filed 2024-11-07 | $817.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$70.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $142.00M 10-Q · filed 2024-08-01 | $1.73B derived: sum of 3 quarters · filed 2025-02-21 | $2.08B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $212.00M 10-Q · filed 2024-05-02 | $1.80B derived: sum of 2 quarters · filed 2025-02-21 | $2.15B derived: sum of 3 quarters · filed 2025-02-21 | $2.06B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $1.59B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.93B derived: sum of 2 quarters · filed 2025-02-21 | $1.84B derived: sum of 3 quarters · filed 2025-02-21 | $2.26B 10-K · filed 2025-02-21 | $1.70B 10-K · filed 2023-02-24 | |||
| 2022-09-30 | $345.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $255.00M derived: sum of 2 quarters · filed 2023-11-03 | $669.00M 10-Q · filed 2023-11-03 | $972.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$90.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $324.00M 10-Q · filed 2023-08-03 | $627.00M derived: sum of 3 quarters · filed 2024-02-23 | $703.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $414.00M 10-Q · filed 2023-05-04 | $717.00M derived: sum of 2 quarters · filed 2024-02-23 | $793.00M derived: sum of 3 quarters · filed 2024-02-23 | $891.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $303.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $379.00M derived: sum of 2 quarters · filed 2024-02-23 | $477.00M derived: sum of 3 quarters · filed 2024-02-23 | $489.00M 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $76.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $174.00M derived: sum of 2 quarters · filed 2022-11-03 | $186.00M 10-Q · filed 2022-11-03 | $359.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $98.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $110.00M 10-Q · filed 2022-08-03 | $283.00M derived: sum of 3 quarters · filed 2023-02-24 | $339.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $12.00M 10-Q · filed 2022-05-04 | $185.00M derived: sum of 2 quarters · filed 2023-02-24 | $241.00M derived: sum of 3 quarters · filed 2023-02-24 | $249.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $173.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $229.00M derived: sum of 2 quarters · filed 2023-02-24 | $237.00M derived: sum of 3 quarters · filed 2023-02-24 | $241.00M 10-K · filed 2023-02-24 | $241.04M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $56.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $64.00M derived: sum of 2 quarters · filed 2021-11-04 | $68.00M 10-Q · filed 2021-11-04 | $67.99M 10-Q · filed 2020-10-30 | $59.81M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $12.00M 10-Q · filed 2021-08-05 | $11.79M 10-Q · filed 2020-08-06 | $3.81M derived: sum of 3 quarters · filed 2022-02-25 | $8.04M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-06 | $4.30M 10-Q · filed 2020-05-07 | -$4.19M derived: sum of 2 quarters · filed 2022-02-25 | $35.00K derived: sum of 3 quarters · filed 2022-02-25 | -$2.65M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$8.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$3.96M derived: sum of 2 quarters · filed 2022-02-25 | -$6.65M derived: sum of 3 quarters · filed 2022-02-25 | -$10.00M 10-K · filed 2022-02-25 | -$9.75M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $4.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $1.54M derived: sum of 2 quarters · filed 2020-10-30 | -$1.81M 10-Q · filed 2020-10-30 | $1.41M 10-Q · filed 2019-11-06 | -$1.77M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | -$2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$6.04M 10-Q · filed 2020-08-06 | -$2.31M 10-Q · filed 2019-08-08 | -$5.99M derived: sum of 3 quarters · filed 2021-02-26 | -$9.62M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | -$3.35M 10-Q · filed 2020-05-07 | -$3.31M 10-Q · filed 2019-05-09 | -$3.31M derived: sum of 2 quarters · filed 2021-02-26 | -$6.94M derived: sum of 3 quarters · filed 2021-02-26 | -$306.00K derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$3.58M derived: sum of 2 quarters · filed 2021-02-26 | $3.05M derived: sum of 3 quarters · filed 2021-02-26 | $5.29M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $3.00M derived: sum of 2 quarters · filed 2019-11-06 | $5.25M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $8.87M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $2.24M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$579.00K 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $7.89M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |